BeOne Medicines (ONC) Reports Q4 Revenue of $1.5 Billion, $1.1 Billion from Lymphoma Treatment
BeOne Medicines AG (NASDAQ:ONC) is among the 12 Best Stocks to Buy and Hold for the Next 2 Years. On February 26, BeOne Medicines AG (NASDAQ:ONC) reported total global revenue of $1.5 billion for the fourth quarter of 2025 and $5.3 billion for 2026, increases of 33% and 40% from the prior-quarter and prior-year periods,…